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Evaluation of hand function in patients
undergoing long term haemodialysis
V Limaye, A Frankham, A Disney, K Pile
Abstract
Objective—Haemodialysis is associated
with the deposition of â2 microglobulin in
musculoskeletal structures, leading to the
syndrome of dialysis related amyloidosis
and impairment of hand function. This
study aimed at assessing hand function
using the Sollerman test in a cross section
of patients undergoing haemodialysis.
Methods—Recipients of haemodialysis
underwent the Sollerman test of hand grip
function, which assesses 20 activities of
daily living using eight grip types, and the
JAMAR grip strength test, visual analogue
scales (VAS) for pain (VAS-P) and func-
tion (VAS-F), and Health Assessment
Questionnaire (HAQ) were determined.
Results—Thirty five subjects (26 male),
with mean age 53.2 years, participated.
The average duration of haemodialysis
was 6.2 years (range one month to 25
years). The median Sollerman score was
77, with 19/35 (54%) patients receiving
haemodialysis having a score below the
lower normal value of 78–80. The log Soll-
erman score correlated poorly with age
(rs=0.16, p=0.35), and significantly with
the HAQ score (rs=−0.66, p<0.00005),
duration of haemodialysis (rs=−0.39,
p<0.05), VAS-F (rs=−0.41, p<0.05), VAS-P
(rs=−0.34, p<0.05), and JAMAR score
(rs=0.57, p<0.05). Sollerman scores were
highly correlated between dominant and
non-dominant hands (rs=0.69, p<000005).
Conclusions—Hand dysfunction is a com-
mon finding among patients undergoing
long term haemodialysis. The Sollerman
test accurately reflects patient function as
measured by HAQ, VAS-F, and grip
strength, but less so pain. Its use for the
early detection of dialysis related amy-
loidosis and in the serial monitoring of the
eVects of hand treatment programmes is
encouraged.
(Ann Rheum Dis 2001;60:278–280)
Haemodialysis in chronic renal failure does not
adequately restore all avenues of normal renal
function. Clinically relevant is the retention
and preferential deposition in musculoskeletal
structures of â2 microglobulin, an 11.8 kDa
polypeptide.1 The clinical manifestations of
this deposition are broadly known as dialysis
related amyloidosis, and include a destructive
arthropathy,2 erosive spondyloarthropathy,3
and bone cysts.4 Carpal tunnel syndrome is
common and, together with flexor tendon con-
tractures and trigger finger, is known to aVect
hand function adversely,5 which may, in turn,
impede activities of daily living.
Measurement of hand function in patients
with dialysis related amyloidosis is not well
described. A single study of hand function used
a method devised for medicolegal purposes
and not primarily to reflect hand grips as
needed in activities of daily living.5 The Soller-
man test assesses unilateral and bilateral hand
grip function in activities of daily living.6 This
test has been validated against other tests of
hand function (Jebsen test of hand function),7 8
and inter-rater coeYcient of reliability is high,
r=0.98 (Doehr SL, unpublished data).
We aimed at undertaking a cross sectional
analysis of hand grip function using the Soller-
man test in patients receiving haemodialysis,
and correlating this test with other measures




Patients receiving hospital or community based
haemodialysis for more than one month,
through the Queen Elizabeth Hospital, were
invited to participate after obtaining their
informed consent. Inflammatory arthritis and
peripheral neuropathy were exclusion criteria.
GENERAL
Demographic data were obtained, along with
details of haemodialysis (frequency, duration,
dialyser type, and membrane), prior renal
transplantation, parathyroidectomy, hand
dominance, carpal tunnel syndrome, and
symptoms of peripheral/axial arthritis. The
visual analogue scale for pain, VAS-P (place a
vertical mark on the line below to represent the
pain you experienced in your hands over the
past 24 hours) and function, VAS-F (consider
the way your hands are aVected and place a
vertical mark on the line below to represent
how you are doing), and the Health Assess-
ment Questionnaire (HAQ) scores were deter-
mined by standard techniques. All subjects
underwent the JAMAR test (JA Preston Corp,
Ontario, Canada) for hand grip strength and
the Sollerman test (Exelfort Pty Ltd, Cottes-
loe) for the dominant (D) and non-dominant
(ND) hands with a single occupational thera-
pist. The JAMAR hand dynamometer meas-
ures grip strength by isometric muscle contrac-
tion, and is performed in the sitting position,
with the shoulder adducted, elbow flexed to
ninety degrees, and forearm and wrist in
neutral positions. The test is performed three
times, and the results averaged to give the final
result.9 Of five possible settings, the second
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setting was used for all subjects, and results
recorded as kilograms of force.
SOLLERMAN TEST
The Sollerman test uses 20 items comprising
activities of daily living tasks; 15 items test
bilateral hand grip function, and seven of the
grips assessed are essential for normal func-
tion. The eight main grip types are tested in the
following proportions: pulp pinch 20%, lateral
pinch 20%, tripod pinch 10%, five finger pinch
15%, diagonal volar grip 15%, transverse volar
grip 14%, spherical volar grip 4%, and
extension grip 2%. Points are assigned to each
item on a five level scale; the final score is the
sum of all items. Possible scores range from
zero to 80; subjects with normal hand function
should achieve scores of 80 and 78–80 in the
dominant and non-dominant hands respec-
tively.
STATISTICAL ANALYSIS
Statistical comparison used the Spearman cor-
relation coeYcient, linear regression analysis,
and Student’s t test (p<0.05 significant). The
study was approved by the Queen Elizabeth
Hospital ethics of human research committee.
Results
Thirty five patients (26 male) aged 24–84 years
(mean (SD) 53.2 (15.2)) participated. Causes
of chronic renal failure were glomerulonephri-
tis (9/35, 26%), unknown cause (9/35, 26%),
reflux nephropathy (5/35, 14%), polycystic
kidney disease, diabetes mellitus, and IgA
nephropathy each 2/35, (6%), Alport’s disease,
pre-eclampsia, Goodpasture’s syndrome,
lithium toxicity, renovascular disease, and
primary amyloidosis each 1/35 (3%). Ten
patients had undergone a previous failed renal
transplantation, with three patients having
received three transplants. The average graft
survival was 4.4 years (range from one never
functioning graft to 28 years). The duration of
haemodialysis (excluding periods of function-
ing renal allografts) ranged from one month to
25 years (mean 6.2 (7.8) years, median 2
years). All patients were dialysed three times a
week for four hours, using bicarbonate buVer,
and predominantly polysulphone membranes
(one patient used a cellulose membrane and
one used a triacetate membrane). The fistula
was in the non-dominant arm in 20/35 (57%)
subjects. Seven patients had undergone para-
thyroidectomy, nine had previous surgically
corrected carpal tunnel syndrome, 17 had
symptoms of peripheral arthritis, and 13 had
symptoms of axial arthropathy.
Table 1 shows the mean, median, and range
of scores obtained for HAQ, VAS-P, VAS-F,
JAMAR-D, JAMAR-ND, Sollerman-D, and
Sollerman-ND. The median Sollerman score
was 77, with 19/35 (54%) patients receiving
haemodialysis having a score below the lower
normal value of 78–80. The frequency distri-
butions for Sollerman scores (dominant and
non-dominant) were skewed (marked cluster-
ing between 73 and 80), hence the scores were
log transformed for statistical analysis. Al-
though the frequency distributions for HAQ,
VAS-P, and VAS-F were also skewed, log trans-
formation was not performed because a large
proportion of subjects had scores of zero.
There was no significant diVerence between
the Sollerman scores for the dominant and
non-dominant hands and therefore other com-
parisons were made with the Sollerman score
for the dominant hand only (table 2). There
was no correlation between Sollerman scores
and age. The Sollerman score correlated most
strongly with the HAQ score but also corre-
lated with the duration of dialysis, VAS-P,
VAS-F, and JAMAR-D.
Discussion
Of the total daily synthesis of â2 microglobulin
(150–200 mg),10 only a small fraction is
removed by haemodialysis. With haemodialy-
sis, the accumulation and deposition of this
polypeptide in musculoskeletal structures leads
to dialysis related amyloidosis. Age above 40
years at the start of dialysis,11 duration of
haemodialysis,12 and the use of cuprophane
membranes are identified risk factors.
The Jebsen test is a norm referenced instru-
ment which provides a quantitative measure of
seven aspects of unilateral hand function, and
assesses the speed, rather than the quality of
the performance.7 The time taken to perform
the Jebsen test is strongly correlated with scores
obtained using the Sollerman test.8 The Soller-
man test is a more sensitive measure of
functional performance than the Jebsen test, as
indicated by the patients’ subjective estimation
of hand function.8 The two tests, however, pro-
vide distinct information, and the test used
depends on the criterion of hand function to be
assessed.
The incidence of impaired hand function in
our group undergoing haemodialysis, as indi-
cated by the Sollerman test, was substantial,
with 19/35 (54%) patients scoring below the
lower normal value. The negative correlation of
the log Sollerman-D score with the HAQ,
Table 1 Range of scores for Health Assessment Questionnaire (HAQ), visual analogue
scales for pain, VAS-P (reflecting the pain felt in the hands in the past 24 hours), and
function, VAS-F (reflecting the patients’ assessment of “how they are doing”), JAMAR






Mean 4.8 18.7 22.2 25.0 22.8 75.6 74.9
SD 5.3 28.8 29.4 11.4 12.1 5.3 5.7
Median 3 2 3 25 21.5 77 77
Range 0–19.0 0–100.0 0–100.0 3.0–48.0 6.0–46.0 53.0–80.0 55.0–80.0
Table 2 Correlation of log Sollerman score in the dominant
hand (Sollerman-D) with age, duration of dialysis,Health
Assessment Questionnaire (HAQ), visual analogue scales for
pain,VAS-P (reflecting the pain felt in the hands in the past
24 hours) and function,VAS-F (reflecting the patients’
assessment of “how they are doing”), JAMAR score in the
dominant hand (JAMAR-D), and the log of the Sollerman
score in the non-dominant hand (Sollerman-ND)
Log Sollerman-D
Age rs =0.16, p=0.35
Duration rs =−0.39, p<0.05
HAQ rs =−0.66, p<0.00005
VAS-P rs =−0.34, p<0.05
VAS-F rs =−0.41, p<0.05
JAMAR-D rs =0.57, p<0.05
Log Sollerman-ND rs =0.69, p<0.000005
rs = Spearman’s correlation coeYcient.
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VAS-P, and VAS-F scores (table 2) indicates
that measurement of hand function by the
Sollerman test accurately reflects the patients’
subjective assessment of pain and functional
limitation. By extrapolation, reducing pain and
improving function should lower the HAQ,
VAS-P, and VAS-F scores, and simultaneously
improve the Sollerman scores. This measure,
therefore, could be used in serial measure-
ments in following up patients with dialysis
related amyloidosis, and documenting objec-
tively the eVect of interventional strategies (for
example, hand treatment programmes).
Once functional limitation from â2 micro-
globulin deposition has developed, the limita-
tion as indicated by the Sollerman test seems to
be bilateral—there was no significant diVer-
ence in the Sollerman scores between the
dominant and non-dominant hands. Grip
strength as indicated by the JAMAR test corre-
lated well with the Sollerman-D score (rs=0.57,
p<0.05) and it is not surprising that hand
functional impairment should occur in parallel
with a reduction in grip strength.
Reduction in the Sollerman-D score with
increasing duration of haemodialysis (table 2)
is biologically plausible, and duration of
haemodialysis is an identified risk factor for the
development of dialysis related amyloidosis.12
The Sollerman score was independent of age
(p=0.35, rs=0.16) within the age range studied
(24–84 years), and this test therefore appears
suitable for a wide age group.
The wide range in age and duration of
haemodialysis of our study group are the major
limitations of this study. Furthermore, al-
though dialysis related amyloidosis was the
presumed cause of hand dysfunction, patients
with other comorbidities aVecting hand func-
tion were excluded. The use of the Sollerman
test in other conditions in which hand dysfunc-
tion is common (for example, rheumatoid
arthritis) has not been evaluated, and applica-
tion of this test to such conditions may prove
similarly beneficial.
The functional consequences of â2 micro-
globulin deposition in the hand can be
debilitating. We have, for the first time, shown
that the Sollerman test reliably measures such
alteration in hand function in activities of daily
living. This test, unlike the HAQ, VAS-P, and
VAS-F, requires active patient participation,
while maintaining an objective, validated scor-
ing system.We propose its use for the detection
of dialysis related amyloidosis, and thereby tar-
get those at risk for the use of the more
biocompatible membranes. Individualised
hand treatment programmes, targeting areas of
deficiency identified by the Sollerman test
should be implemented, and the use of this test
in serial measurements is encouraged.
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